Skip to main content

Table 6 Primary outcomes from baseline – Adverse Events

From: Efficacy and safety of interventions to control myopia progression in children: an overview of systematic reviews and meta-analyses

Outcome

Comparison

Number of subjects (primary studies)

Measure of effect (95% CI)

Direction of effect

I2 (%)

Allergic or hypersensitivity reactions or discomfort

1% atropine versus control

446 (2)

OR = 8.91 (1.04, 76.03)

Favours control

0

Blurred near vision

1% atropine versus control

540 (2)

OR = 9.47 (1.17, 76.78)

Favours control

0

Contact lens-related discomfort/Unwillingness to wear contact lenses

Concentric ring bifocal SCLs versus SVSCLs

261 (2)

OR = 0.95 (0.49, 1.81)

Favours concentric ring bifocal SCLs

0

Mild corneal erosion

ΟΚ versus SCLs or SVLs

151 (2)

0R = 4.56 (0.49, 42.25)

Favours SCLs/SVLs

0

Papillae/Follicles

2% pirenzepine gel versus control

323 (3)

OR = 3.21 (0.95, 10.88)

Favours control

74

Medication residue on eyelids or eye

2% pirenzepine gel versus control

323 (3)

OR = 0.77 (0.38, 1.59)

Favours pirenzepine

33

Abnormality of accommodation

2% pirenzepine gel versus control

323 (3)

OR = 16.92 (6.27, 45.64)

Favours control

0

Itching, eye

2% pirenzepine gel versus control

323 (3)

OR = 1.01 (0.54, 1.90)

No difference

0

Visual acuity decreased (subjectively)

2% pirenzepine gel versus control

323 (3)

OR = 3.89 (0.93, 16.27)

Favours control

33

Injection

2% pirenzepine gel versus control

323 (3)

OR = 0.92 (0.22, 3.73)

Favours pirenzepine

74

Fluorescein staining

2% pirenzepine gel versus control

323 (3)

OR = 0.57 (0.23, 1.44)

Favours pirenzepine

45

Burn/Sting, eye, on instillation

2% pirenzepine gel versus control

323 (3)

OR = 1.84 (0.76, 4.46)

Favours control

0

Eye/Vision, blurred

2% pirenzepine gel versus control

323 (3)

OR = 1.17 (0.52, 2.63)

Favours control

0

Erythema, eyelids

2% pirenzepine gel versus control

110 (2)

OR = 0.69 (0.01, 41.23)

Favours pirenzepine

76

Eyelid abnormality

2% pirenzepine gel versus control

110 (2)

OR = 1.73 (0.27, 11.12)

Favours control

0

Photophobia

2% pirenzepine gel versus control

110 (2)

OR = 1.57 (0.35, 6.96)

Favours control

0

Eye pain

2% pirenzepine gel versus control

110 (2)

OR = 2.07 (0.33, 12.98)

Favours control

0

Cough, increased

2% pirenzepine gel versus control

323 (3)

OR = 1.06 (0.59, 1.92)

No difference

0

Infection, respiratory

2% pirenzepine gel versus control

297 (2)

OR = 1.32 (0.69, 2.51)

Favours control

0

Rhinitis/Sinusitis

2% pirenzepine gel versus control

323 (3)

OR = 1.08 (0.42, 2.76)

No difference

28

Fever

2% pirenzepine gel versus control

297 (2)

OR = 1.07 (0.51, 2.24)

No difference

0

Abdominal pain

2% pirenzepine gel versus control

323 (3)

OR = 2.42 (0.88, 6.62)

Favours control

0

Headache

2% pirenzepine gel versus control

323 (3)

OR = 1.30 (0.66, 2.56)

Favours control

0

Flu syndrome

2% pirenzepine gel versus control

297 (2)

OR = 0.54 (0.26, 1.13)

Favours pirenzepine

0

Pharyngitis

2% pirenzepine gel versus control

323 (3)

OR = 1.07 (0.48, 2.37)

No difference

0

Rash/Allergic reaction

2% pirenzepine gel versus control

323 (3)

OR = 1.77 (0.51, 6.12)

Favours control

22

Cold, common

2% pirenzepine gel versus control

110 (2)

OR = 0.60 (0.25, 1.42)

Favours pirenzepine

0

Accidental injury

2% pirenzepine gel versus control

110 (2)

OR = 2.32 (0.74, 7.22)

Favours control

0

  1. CI confidence interval, OK Orthokeratology, OR odds ratio, RR risk ratio, SCLs soft contact lenses, SVLs single vision lenses, SVSCLs single vision soft contact lense